← Human Trials & Peer-Reviewed Studies
Nicotine Patch Alters Patterns of Cigarette Smoking-Induced Dopamine Release: Patterns Relate to Biomarkers Associated With Treatment Response
Plain-language guide to PMID 35100429 (2022): placebo-controlled randomized controlled trial study of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 35100429
- Journal
- Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Zakiniaeiz Y et al. (11 authors)
- DOI
- 10.1093/ntr/ntac026
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
Following 1-week under NIC and then overnight abstinence, smokers participated in a 90-minute [11C]raclopride positron emission tomography scan and smoked a cigarette while in the scanner.
Identical procedures were followed for the PBO scan.
A time-varying kinetic model was used at the voxel level to model transient dopamine release peaking instantaneously at the start of the stimulus and decaying exponentially.
Why It Was Studied
Tobacco smoking is a major public health burden.
Nicotine acts on nicotinic-acetylcholine receptors on dopamine terminals to release dopamine in the ventral and dorsal striatum encoding reward and habit formation, respectively.
Who Took Part
PubMed tags the participants as women only.
How the Study Was Run
The design is described as randomized and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.
Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.
A time span of 1 week appears in the methods.
What Was Measured
Topics PubMed links to this paper include Biomarkers, Cigarette Smoking, Dopamine, Nicotine, Raclopride, Receptors, Nicotinic and Smoking Cessation.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) over 1 week.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2022 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.